Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Legend Biotech Corporation filings document foreign private issuer current reports, operating updates, governance actions, registration statements, and equity-plan disclosures for a cell therapy biopharmaceutical company. Its Form 6-K reports cover CARVYKTI® preliminary sales information received through the Janssen collaboration, quarterly and annual financial-result releases, corporate presentations, and clinical updates involving the CARTITUDE program and LUCAR-G39D.
The company’s regulatory disclosures also record board appointments and resignations, audit committee leadership, director compensation under restricted share unit plans, and related-party matters involving GenScript. Incorporated Form F-3 and Form S-8 references connect current reports with securities registration and incentive-plan filings, while risk language addresses forward-looking statements, product development, collaboration economics, and commercialization of CAR-T therapies.
Legend Biotech Corporation (LEGN) – Form 144 filing
The filing, marked as LIVE, notifies the SEC of a proposed Rule 144 sale of 307 American Depositary Shares (ADS), valued at approximately $10,551.59. Fidelity Brokerage Services LLC is listed as broker, and the sale is expected to occur on or about 24 June 2025 on NASDAQ.
The ADS were acquired on 20 June 2025 through the vesting of restricted stock awarded as compensation. Outstanding ADS total 367,298,315; therefore, the planned disposition represents less than 0.0001 % of shares outstanding, indicating an immaterial effect on float or control.
The filer, identified in prior activity as Corazon Sanders, previously sold an identical lot of 307 ADS on 25 March 2025 for gross proceeds of $11,153.31. No relationship to the issuer, 10b5-1 plan details, or additional insider roles are disclosed. The signer attests to possessing no undisclosed material adverse information.